Oragenics Inc (OGEN) Stock Price & Analysis
Oragenics Inc (OGEN) fell 0.73% to USD 0.6 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
OGEN last closed at USD 0.6; the session ranged USD 0.58–0.6 on volume of 24,454 shares. Market capitalization is $2.71M, with a 52-week range of USD 0.5–5.19 (ASE). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 0.73% (down) |
| Previous Close | USD 0.6 |
| Open | USD 0.59 |
| Day Range | USD 0.58 – 0.6 |
| 52-Week Range | USD 0.5 – 5.19 |
| Volume | 24,454 shares |
| Market Cap | $2.71M |
| Exchange | ASE |
Technical Analysis (OGEN)
Nexqual's technical model rates OGEN "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.01 (neutral) |
| vs SMA50 | Below (USD 0.61) |
| MACD | -0 (negative) |
Analyst Ratings (OGEN)
Wall Street analysts rate OGEN "None", per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | None |
|---|
Earnings (OGEN)
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (OGEN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -311.00% |
| Debt / Equity | 0.91 |
| Current Ratio | 5.73 |
| Total Cash | $6.11M |
| Total Debt | $56,134 |
| Free Cash Flow | $-5.96M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (OGEN)
Nexqual rates Oragenics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -311%, ROA -105.6% |
Ownership (OGEN)
| Insider Ownership | +1.93% |
|---|---|
| Institutional Ownership | +5.79% |
| Shares Outstanding | 4.51M |
| Float | 4.41M |
| Short % of Float | +15.73% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (OGEN)
Oragenics Inc is led by Janet Huffman (age 53), CEO, President, CFO, Secretary & Treasurer, per Nexqual as of June 10, 2026 at 00:27 UTC.
| CEO, President, CFO, Secretary & Treasurer | Janet Huffman (age 53) |
|---|---|
| Executive Chairman | Charles L. Pope (age 73) |
Major Backers & Investors (OGEN)
Notable institutional backers of Oragenics Inc include Fidelity, Pathstone Holdings, LLC, Two Sigma Securities, LLC, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.4% |
| Pathstone Holdings, LLC | 1.22% |
| Two Sigma Securities, LLC | 0.45% |
| HRT Financial LP | 0.41% |
| Virtu Financial LLC | 0.39% |
| UBS Group AG | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.44% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Oragenics Inc's Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- The first developer to receive FDA marketing approval for an orphan drug is entitled to a seven-year exclusive marketing period in the U.S. for the orphan drug indication.
- Interim patent extensions are not available for a drug for which an NDA has not been submitted.   Section 505(b)(2) New Drug Applications   Most drug products obtain FDA marketing approval pursuant to an NDA or an ANDA.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAGX | Jaguar Health, Inc. | USD 2.82 | ▲ 0.71% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 11.46 | ▲ 3.52% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| IGC | IGC Pharma, Inc. | USD 0.29 | ▼ 1.72% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.